It may be a highly significant targeting molecule to promote the development of therapeutic molecules of either synthetic or natural origin to control the activity of FN3K, subsequently to confer Nrf2 in the glycated state in cancer cells including breast cancers. Here, FN3K is linked to breast cancer.